Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

WHO, UNICEF Say Vitamin A, Deworming Interventions Safe, In Response To Alleged Deaths, Sickness In Bangladesh
The WHO and UNICEF on Tuesday said that vitamin A supplements and deworming tablets are safe, after two deaths and the "sickness of hundreds" were alleged among the children who received the interventions during a nationwide campaign in Bangladesh, Bernama.com reports (Bernama.com, 6/9).
generic viagra online
Normal Development Of Cells With Abnormal Numbers Of Nuclei
Most of our cells contain a single nucleus that harbors 46 chromosomes (DNA and protein complexes that contain our genes). However, during normal postnatal development, liver cells containing two nuclei, each of which have 46 chromosomes, appear. These cells, which are known as binucleated tetraploid hepatocytes, arise in all mammals as a result of failure of the cellular process cytokinesis (the process by which the bulk of a cell, excluding the nucleus, divides to form two "daughter" cells). New insight into the failure of this process has now been provided by Chantal Desdouets and colleagues, at Institut Cochin, France, who have identified a cellular signaling pathway that leads to cytokinesis failure and the formation of binucleated tetraploid hepatocytes in rodents.
News of the day
Almirall Announces Filing Sativex(R) - For Treatment Of Spasticity In Multiple Sclerosis - Regulatory Submission
Almirall announces today that the file for a regulatory submission for Sativex® for the treatment of spasticity due to multiple sclerosis has been submitted in UK and Spain under the European decentralised procedure. The UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), is acting as Reference Member State and has validated the application.
Health Insurance

Cubist Pharmaceuticals Initiates Phase 2 Trial In Europe For Therapy To Reduce Blood Loss During Surgery In High Risk Patients

Cubist Pharmaceuticals, Inc. (Nasdaq: CBST), a leading acute care therapeutics company, announced that it has begun dosing in the CONSERV™-2 clinical trial with ecallantide. CONSERV-2, being conducted in Europe, is a Phase 2 trial that will investigate ecallantide"s effect on surgical blood loss volume in cardiac surgery patients who are on cardiopulmonary bypass and are at a high risk of bleeding. The trial is expected to enroll 300 subjects. Ecallantide is a potent inhibitor of plasma kallikrein, and CONSERV-2 will evaluate the effects of plasma kallikrein inhibition in the trial population. Surgical environments, such as those involving the trial population, are associated with the activation of plasma kallikrein and subsequent activation of coagulation, fibrinolytic, and inflammatory cascades, which likely contribute to blood loss and blood transfusion requirements in the perioperative setting. "The dosing of patients in the CONSERV-2 trial represents another important milestone in the continued evaluation of ecallantide for the reduction of blood loss during on-pump cardiac surgery, an area of significant unmet medical need. We remain on track for a mid-2010 end-of-phase 2 meeting with the FDA, and we anticipate that the results of this trial and the ongoing CONSERV-1 trial will provide meaningful insights into the optimal design of subsequent Phase 3 trials," said Santosh Vetticaden, PhD, MD, Senior Vice President, Clinical Development and Chief Medical Officer. "This represents another important milestone for our growing pipeline of novel acute care therapeutics" said Steve Gilman, PhD, Chief Scientific Officer and Senior Vice President, Discovery and Nonclinical Development. In April 2008, Cubist announced an exclusive North American and European license and collaboration agreement with Dyax Corp. (NASDAQ: DYAX) for the development and commercialization of the intravenous formulation of ecallantide for surgical indications. The first indication being sought by Cubist for ecallantide is the reduction of blood loss during on-pump cardiac surgery. Cubist Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009